Quinic Acid Derivative for CD28 Binding and T-Cell Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for suppressing T-cell activation, such as anti-CD28 antibodies, face issues with stability, cytotoxicity, and limited oral availability, making them unsuitable for treating autoimmune diseases and allergies.
Innovation Solution
A cynarin-analogous quinic acid derivative is developed, which binds to CD28 and blocks T-cell activation, prepared through a two-step process involving acid catalysts and microwave irradiation, reducing cytotoxicity and enhancing stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-CD28 antibodies are used to block T-cell activation, then T-cell activation is suppressed, but the antibodies have poor stability and limited oral availability
Solution Approach 1:
The patent creates a small molecule compound that copies the binding function of anti-CD28 antibodies. The compound (2S,3S,4S)-3,4-dihydroxy-2-((1-methylcyclopropyl)methoxycarbonyl)cyclohexanecarboxylic acid or its salts mimics the antibody's ability to block CD28-CD80/86 interaction, providing stability and oral availability that antibodies lack while maintaining the therapeutic function of suppressing T-cell activation.
2Reliability
If cynarin is used to block CD28, then T-cell activation is suppressed, but the compound exhibits cytotoxicity
Solution Approach 1:
The patent extracts and modifies the active pharmacophore from cynarin. By isolating the essential structural features needed for CD28 binding and removing or modifying the cytotoxic portions of the cynarin molecule, the invention creates a derivative that retains CD28-blocking efficacy while reducing cytotoxicity to acceptable levels for therapeutic use.
Solution Approach 2:
The patent systematically modifies chemical parameters of the cynarin structure, specifically adjusting the substitution patterns on the benzene ring and the ester group configuration. These parameter changes optimize the balance between CD28 binding affinity (efficacy) and cellular compatibility (reduced cytotoxicity), resulting in therapeutically viable compounds.
3Ease of manufacture
If small compounds mimicking metabolites are used to block target pathways, then oral stability is improved, but the compounds may have reduced efficacy compared to antibodies
Solution Approach 1:
The patent optimizes multiple chemical parameters simultaneously - molecular size, functional group configuration, stereochemistry, and lipophilicity - to achieve the right balance between oral stability and CD28 binding efficacy. The specific structural features (hydroxyl groups, carboxylic acid/ester groups, cyclic structure) are tuned to maintain high affinity for CD28 while ensuring metabolic stability for oral administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The derivative effectively suppresses T-cell activation, as demonstrated by reduced IL-2 production and cytotoxicity, with improved stability and efficacy in treating autoimmune diseases, allergies, and transplant rejections, while minimizing side effects.
Implementation Method 1
treats a quinic acid with a strong acid and a first reagent (R2＝O) to generate an intermediate
Implementation Method 2
forms a lactone immediate in the presence of acid catalyst
Implementation Method 3
treats the lactone immediate with an amine reagent to generate the quinic acid derivative product under microwave irradiation
Data Source
AI summary
The present invention relates to a quinic acid derivative, preparation process of the same and pharmaceutical uses thereof. The quinic acid derivative has a quinic acid-like structure which binds to CD28, blocks T-cell signal 2 pathway via CD28, and suppresses T-cell activation. The C-1 carboxyl group, the C-3 hydroxyl group and the C-4 hydroxyl group of quinic acid are modified to attenuate the cytotoxicity of the quinic acid derivative. The preparation process of the quinic acid derivative comprises 2 steps of: treating quinic acid with the first reagent in the presence of the acid catalyst to form an immediate; and treating the immediate with the second reagent to from the quinic acid derivative. With the ability to suppress T-cell activation, the quinic acid derivative is used to treats an autoimmune disease, an allergy, transplant rejection or other related immune disorder.